落新妇甙对大鼠肺移植排斥反应抑制作用的实验研究
|
摘要
第一部分大鼠同种异体原位肺移植模型的建立
目的:通过大鼠套管法吻合技术建立大鼠左侧原位肺移植模型。方法:将60只SPF级SD大鼠随机分为供、受体两组,采用三套管吻合技术完成大鼠肺移植模型。结果:30例手术中,供肺灌注到摘取时间(10±1)分钟,供肺完成套管时间(10±4)分钟,供体动静脉、支气管吻合时间(15±2)分钟,移植肺热缺血时间(16±2)分钟,冷缺血时间(30±5)分钟,手术平均时间(80±10)分钟,术后15天生存率达86%,其中两例死于急性肺水肿,一例死于肺静脉栓塞,一例死于对侧气胸。结论:三套管大鼠同种异体肺移植模有效、可靠,为临床肺移植提供了较好的实验基础,但是模型操作复杂,需要长时间的学习和反复操作来提高肺移植模型的稳定性。
第二部分落新妇甙对大鼠肺移植排斥反应的抑制作用
目的:运用排斥反应分级及观察落新妇甙对大鼠移植肺中支气管肺泡灌洗液诱导肺成纤维细胞胶原增生的抑制作用实验,探讨落新妇甙对大鼠肺移植排斥反应的抑制作用。方法:采用大鼠左侧原位肺移植模型。随机将肺移植后的60只大鼠分为4组:A组肺移植后用生理盐水(1ml/天)灌胃,B组肺移植后用环孢素A (5mg/kg/天)灌胃,C组肺移植后用落新妇甙(1mg/kg/天)灌胃,D组肺移植后用环孢素A (2.5mg/kg/天)及落新妇甙(1mg/kg/天)灌胃。术后第30天(每组抽取5只大鼠)切取移植肺观察肺急性排斥反应分级情况;另外每组10只大鼠,取受体支气管肺泡灌洗液。用收集的支气管肺泡灌洗液在体外刺激人胚胎成纤维细胞,通过MTT比色法和酶联免疫(ELISA)法分别检测人胚肺成纤维细胞的增殖及Ⅰ型胶原的合成,并对检测结果进行分析。结果:(1)B组、C组及D组移植肺排斥反应分级均低于A组(P<0.01);D组移植肺急性排斥反应最轻,优于C组(P<0.05)和B组(P<0.01)。(2)受者移植肺中支气管肺泡灌洗液显著促进了人胚肺成纤维细胞的增殖和胶原合成;(3)B、C、D组的支气管肺泡灌洗液诱导的人胚肺成纤维细胞Ⅰ型胶原合成有显著的抑制作用(P<0.05)。结论:落新妇甙可抑制大鼠移植肺中支气管肺泡灌洗液诱导的人胚肺成纤维细胞的增殖及胶原合成,对大鼠肺移植后的闭塞性细支气管炎具有抑制作用;对肺移植排斥反应有较强的抑制作用,并与环孢素A具有协同作用。
第三部分落新妇甙对大鼠肺移植急性排斥反应抑制作用的机制研究
实验一落新妇甙对肺移植大鼠活化T细胞的动态影响
目的:观察落新妇甙对大鼠移植肺活化T细胞的影响及动态变化,探讨落新妇甙对大鼠移植肺活化T细胞的作用。方法:采用大鼠左侧单肺原位移植模型。大鼠10只不做移植,抽取外周血作为空白对照;随机将肺移植后的40只大鼠分为2组:A组肺移植后用生理盐水(1ml/天)灌胃,B组肺移植后落新妇甙(1mg/kg/天)灌胃。移植前(空白对照)、术后第2天、术后第5天,分别用荧光标记抗体双染色结合流式细胞技术检测各阶段大鼠T细胞表达的活化抗原CD69、CD25和CD71的表达。结果:术后第2天,各组检测的CD69、CD25和CD71抗原均显著高于对照组(P<0.01),且B组和A组有统计学差异(P<0.05),显示术后第2天,活化T细胞增加,但落新妇甙能显著抑制T细胞的活化。术后第5天,B组CD69、CD25和CD71抗原基本降至正常水平,显著低于A组。结论:落新妇甙能显著抑制急性排斥反应诱导的T细胞活化,对肺移植排斥反应有较强的抑制作用。
实验二落新妇甙诱导移植肺活化T细胞凋亡减轻急性排斥反应
目的:探讨落新妇甙对大鼠肺移植后机体急性排斥反应的影响和机制。方法:建立大鼠左肺原位移植模型,术后将受体大鼠随机分为两组:对照组和实验组。对照组术后生理盐水1ml/天灌胃,实验组术后落新妇甙1mg/kg/天灌胃,观察肺移植的存活时间、大鼠脾细胞T淋巴细胞转化率和脾淋巴细胞IL-2活性,以及外周血中活化T细胞凋亡。结果:与对照组相比,实验组脾细胞T淋巴细胞转化率明显降低,两组差异有显著意义(P<0.05)。移植大鼠脾淋巴细胞IL-2活性在实验组中为4.25±2.65UI/ml,对照组IL-2活性为23.46±1.82UI/ml,两组有显著差异(P<0.01)。实验组能有效的诱导急性排斥反应中活化T细胞凋亡。结论落新妇甙通过下调IL-2产生和抑制体内IFN-γmRNA,诱导活化T细胞凋亡,抑制T淋巴细胞增殖分化,广泛抑制了以T细胞为主的肺移植术后急性排斥反应,从而延长大鼠肺移植的存活时间。
实验三活化T细胞信号凋亡传导通路在落新妇甙抑制肺移植排斥反应中作用
目的:用大鼠左肺原位移植模型,探讨落新妇甙对大鼠肺移植排斥反应中活化T细胞p38丝裂原激活蛋白激酶(p38MAPK)和PI3K/Akt信号传导通路的影响。方法:建立大鼠左肺原位移植模型,在第30天提取大鼠外周血分离活化T细胞进行体外培养,并进行实验分组,A~D组。A组(对照组),行细胞培养;B组(落新妇甙组),培养液中加入落新妇甙15mg/L;C组,落新妇甙(15mg/L)加p38MAPK抑制剂SB203580(5μmol/L);D组,术后每天落新妇甙(15mg/L)加PI3K/Akt抑制剂LY294002(10μmol/L)。TUNEL法检测T淋巴细胞凋亡情况。RT-PCR和Western blot法检测T细胞p38MAPK和PI3K及Akt下游表达的情况。结果:B组(落新妇甙组)T细胞凋亡指数和p38MAPK表达明显高于对照组,而PI3K/Akt明显低于对照组。C组(落新妇甙加p38MAPK抑制剂组)T细胞凋亡和p38MAPK表达均明显低于B组(落新妇甙组)(P<0.01),PI3K/Akt明显高于对照组,但均与对照组无显著差异(P>0.05)。D组(落新妇甙加PI3K/Akt抑制剂LY294002组)T细胞凋亡和PIK3/Akt表达明显高于对照组,p38MAPK明显低于对照组。结论:落新妇甙诱导大鼠肺移植排斥反应中活化T细胞凋亡与其激活p38MAPK信号传导通路、及抑制PI3K/Akt信号传导通路有关。
SECTION ONE The Establishment of Orthotopic Left Pulmonary Allograft Model in Rats
Objective: To establish rat orthotopic left lung allograft transplantation model by the“cuff-like”vessel and bronchial anastomosis technique. Methods: Sixty male Sprague-Dawley rats were randomly allocated to donors and recipients. Thirty left lung transplantation were performed by using the“cuff-like”vessel and bronchial anastomosis technique. Results: All rats were successfully performed orthotopic left lung allograft transplantation. The mean time for the donor lung (from perfusion to the harvest) was (10±1)mins; the mean time for cuff the vessel and bronchus was (10±4)mins; the mean time for anastomoses was (15±2)mins. The mean operative time was (80±10)mins. The 15d survival rates of rats who received transplants were 86%. Among the rats who received transplants, 2 died of pulmonary edema, 1 died of pulmonary thrombosis, the rest one dies of pneumothorax of the right side. Conclusion: Rat orthotopic left lung transplantation with successive anastomosis in cavity is a valid, reproducible, single and cheap model for studying donor lung preservation, ischemia-reperfusion, acute rejection and chronic rejection about lung transplantation.
SECTION TWO Suppression effect of Astilbin on lung allograft rejection in rats
Objective: Using histopathological rejection grade and observeing the local fibrogenesis to study the suppression effect of Astilbin on lung allograft rejection in rats. Methods: The model of rat left lung transplantation was set up.Sixty lung transplanted rats were divided in to 4 groups randomly: group A were fed with normal saline 1ml per day, group B were fed with CsA 5mg/kg per day, group C were fed with Astilbin 1mg/kg per day, and group D were fed with Astilbin 1mg/kg per day aud CsA 2.5mg/kg per day. Histopathological rejection grade of the lung graft were analyzed in after 30 days (5 rats of each group were chosen). BALF(10 rats of each group were chosen) collected from recipients rats treated with drugs while undergoing rat orthotopic left lung transplantation model was used to stimulate human lung fibroblast cells in vitro. Fibroblast proliferation and typeⅠcollagen synthesis was dectected respectively by MTT and ELISA to evaluate the effect of astilbin. Results: (1) In group B , C and D, the histopathological rejection grade of the lung graft was significantly lower as compared with group A. The histopathological rejection grad of the grafts in group D was significantly lower as compared with group C (P<0.05) and group B (P<0.01). (2) In vitro, the BALF induced fibroblast proliferation and typeⅠcollagen synthesis; (3) Group B, C and D significantly decreased human lung fibroblast cells profliferation for stimulation of the BLAF, especially in Group D (P<0.05) Conclusions: Astilbin significantly decreased human lung fibroblast cells proliferation and typeⅠcollagen synthesis for stimulation of BLAF collected from recipients rats treated with drugs while undergoing lung transplantation, suggesting astilbin may inhibit obliterating bronchiolitis after lung transplantation. Astilbin can suppress lung allograft rejection, and has synergistic reaction with CsA.
SECTION THREE The Mechanism of Astilbin on the Suppression of Lung Allograft Rejection PART ONE
Expression and Implication of CD69, CD25 and CD71 on CD3+ lymphocytes in peripheral blood in the rats with lung transplantation using astilbin
Objectives: To investigate the expression and implication of CD69, CD25 and CD71 on CD3+ lymphocytes in peripheral blood in the rats with lung transplantation using astilbin. Methods: The model of rat left lung transplantation was set up. Ten rats were taking peripheral blood as the control group. Forty lung transplanted rats were divided in to 2 groups randomly: group A were fed with normal saline 1ml per day, group B were fed with Astilbin 1mg/kg per day The lymphocytes from the peripheral blood in rats in different periods and were immunologically labeled by CD3·PE and CD69/CD25/CD71·FIFC. CD3/ CD69, CD3 /CD25 and CD3/CD71 were determined by flow cytometry (FCM). Results: The levels of CD3/ CD69, CD3 /CD25 and CD3/CD71 were markedly higher in the 2 days after the lung transplantation, which means the activated T cells were related to the lung allograft acute rejection. On the 5 days after the lung transplantation, the levels of CD3/ CD69 in group B were significant lower in the group A,(P<0.01), which means the astilbin act on the activated T cells and protect the allograft. Conclusion: Astilbin can act on the activated T cells and suppress lung allograft rejection maybe partially related to its effect in activated T cells.
PART TWO Effect of astilbin on the inducement of apoptosis in activated T cells to suppress acute rejection on rat lung transplantation model.
Objective:To study the suppression effect of Astilbin on lung allograft rejection in rats. Methods: The model of rat left lung transplantation was set up. sixty lung transplanted rats were divided in to 2 groups randomly: control group were fed with normal saline 1ml per day, astilbin group were fed with Astilbin 1mg/kg per day. Survival time of each group, activity of IL-2 in spleen lymph cells , transforming rate of T cells in spleen and apoptosis of T cells were observed. Results: Transforming rate of T cells in spleen was significant lower in the astilbin group than the control group. Activity of IL-2 in spleen lymph cells was 4.25±2.65UI/ml and 23.46±1.82UI/ml respectively in the astilbin group and the control group. There were significant difference between two groups (P<0.05). The astilbin group can effectively derive apoptosis of activated T cells in acute rejection. Conclusions: Astilbin can suppress lung allograft rejection maybe partially related to its lower the IL-2 concentration and IFN-γmRNA of activated T cells , which inducement of apoptosis in activated T cells.
PART THREE Effect of astilbin on activation of p38MAPK and suppression of PI3K/Akt signal pathway in activated T cells of rat lung transplantation model with acute rejection.
Objective: To investigate the effect of astilbin on activation of p38 mitogen activated protein kinase (p38MAPK) and suppression of PI3K/Akt in activated T cells of rat lung transplantation model with acute rejection. Methods: The model of rat left lung transplantation was established. At the day30, activated T cells were taken and cultured. The cultured activated T cells were divided into four groups: Group A: control group, were cultured with PBS; Group B: astilbin group, add astilbin (15mg/L); Group C: add Astilbin(15mg/L) and SB203580(5μmol/L); Group D, Astilbin+LY294002(10μmol/L). Apoptosis of T cells were observed by TUNEL. The expression of p38MAPK and PI3K/Akt were measured by RT-PCR and Western blot. Results: Apoptosis indexes and the expression of p38MAPK in activated T cells in Group B were found significant higher than those of the Group A, while PI3K/Akt was significant lower than Group A.(P<0.01). Apoptosis indexes and the expression of p38MAPK in activated T cells in Group B were found significant higher than those of the Group C, while PI3K/Akt was significant lower than Group C.(P<0.01). Apoptosis indexed and the expression of PI3K/Akt in Group D was significant higher than Group A, while the p38MAPK was significant lower than Group A.(P<0.01).Conclusion: Astilbin induces apoptosis of activated T cells of lung transplantation maybe partially related to its activation expression of p38MAPK and suppression of PI3K/Akt signal pathway. Key words: lung transplantation; astilbin, p38MAPK, PI3K/Akt
目的:通过大鼠套管法吻合技术建立大鼠左侧原位肺移植模型。方法:将60只SPF级SD大鼠随机分为供、受体两组,采用三套管吻合技术完成大鼠肺移植模型。结果:30例手术中,供肺灌注到摘取时间(10±1)分钟,供肺完成套管时间(10±4)分钟,供体动静脉、支气管吻合时间(15±2)分钟,移植肺热缺血时间(16±2)分钟,冷缺血时间(30±5)分钟,手术平均时间(80±10)分钟,术后15天生存率达86%,其中两例死于急性肺水肿,一例死于肺静脉栓塞,一例死于对侧气胸。结论:三套管大鼠同种异体肺移植模有效、可靠,为临床肺移植提供了较好的实验基础,但是模型操作复杂,需要长时间的学习和反复操作来提高肺移植模型的稳定性。
第二部分落新妇甙对大鼠肺移植排斥反应的抑制作用
目的:运用排斥反应分级及观察落新妇甙对大鼠移植肺中支气管肺泡灌洗液诱导肺成纤维细胞胶原增生的抑制作用实验,探讨落新妇甙对大鼠肺移植排斥反应的抑制作用。方法:采用大鼠左侧原位肺移植模型。随机将肺移植后的60只大鼠分为4组:A组肺移植后用生理盐水(1ml/天)灌胃,B组肺移植后用环孢素A (5mg/kg/天)灌胃,C组肺移植后用落新妇甙(1mg/kg/天)灌胃,D组肺移植后用环孢素A (2.5mg/kg/天)及落新妇甙(1mg/kg/天)灌胃。术后第30天(每组抽取5只大鼠)切取移植肺观察肺急性排斥反应分级情况;另外每组10只大鼠,取受体支气管肺泡灌洗液。用收集的支气管肺泡灌洗液在体外刺激人胚胎成纤维细胞,通过MTT比色法和酶联免疫(ELISA)法分别检测人胚肺成纤维细胞的增殖及Ⅰ型胶原的合成,并对检测结果进行分析。结果:(1)B组、C组及D组移植肺排斥反应分级均低于A组(P<0.01);D组移植肺急性排斥反应最轻,优于C组(P<0.05)和B组(P<0.01)。(2)受者移植肺中支气管肺泡灌洗液显著促进了人胚肺成纤维细胞的增殖和胶原合成;(3)B、C、D组的支气管肺泡灌洗液诱导的人胚肺成纤维细胞Ⅰ型胶原合成有显著的抑制作用(P<0.05)。结论:落新妇甙可抑制大鼠移植肺中支气管肺泡灌洗液诱导的人胚肺成纤维细胞的增殖及胶原合成,对大鼠肺移植后的闭塞性细支气管炎具有抑制作用;对肺移植排斥反应有较强的抑制作用,并与环孢素A具有协同作用。
第三部分落新妇甙对大鼠肺移植急性排斥反应抑制作用的机制研究
实验一落新妇甙对肺移植大鼠活化T细胞的动态影响
目的:观察落新妇甙对大鼠移植肺活化T细胞的影响及动态变化,探讨落新妇甙对大鼠移植肺活化T细胞的作用。方法:采用大鼠左侧单肺原位移植模型。大鼠10只不做移植,抽取外周血作为空白对照;随机将肺移植后的40只大鼠分为2组:A组肺移植后用生理盐水(1ml/天)灌胃,B组肺移植后落新妇甙(1mg/kg/天)灌胃。移植前(空白对照)、术后第2天、术后第5天,分别用荧光标记抗体双染色结合流式细胞技术检测各阶段大鼠T细胞表达的活化抗原CD69、CD25和CD71的表达。结果:术后第2天,各组检测的CD69、CD25和CD71抗原均显著高于对照组(P<0.01),且B组和A组有统计学差异(P<0.05),显示术后第2天,活化T细胞增加,但落新妇甙能显著抑制T细胞的活化。术后第5天,B组CD69、CD25和CD71抗原基本降至正常水平,显著低于A组。结论:落新妇甙能显著抑制急性排斥反应诱导的T细胞活化,对肺移植排斥反应有较强的抑制作用。
实验二落新妇甙诱导移植肺活化T细胞凋亡减轻急性排斥反应
目的:探讨落新妇甙对大鼠肺移植后机体急性排斥反应的影响和机制。方法:建立大鼠左肺原位移植模型,术后将受体大鼠随机分为两组:对照组和实验组。对照组术后生理盐水1ml/天灌胃,实验组术后落新妇甙1mg/kg/天灌胃,观察肺移植的存活时间、大鼠脾细胞T淋巴细胞转化率和脾淋巴细胞IL-2活性,以及外周血中活化T细胞凋亡。结果:与对照组相比,实验组脾细胞T淋巴细胞转化率明显降低,两组差异有显著意义(P<0.05)。移植大鼠脾淋巴细胞IL-2活性在实验组中为4.25±2.65UI/ml,对照组IL-2活性为23.46±1.82UI/ml,两组有显著差异(P<0.01)。实验组能有效的诱导急性排斥反应中活化T细胞凋亡。结论落新妇甙通过下调IL-2产生和抑制体内IFN-γmRNA,诱导活化T细胞凋亡,抑制T淋巴细胞增殖分化,广泛抑制了以T细胞为主的肺移植术后急性排斥反应,从而延长大鼠肺移植的存活时间。
实验三活化T细胞信号凋亡传导通路在落新妇甙抑制肺移植排斥反应中作用
目的:用大鼠左肺原位移植模型,探讨落新妇甙对大鼠肺移植排斥反应中活化T细胞p38丝裂原激活蛋白激酶(p38MAPK)和PI3K/Akt信号传导通路的影响。方法:建立大鼠左肺原位移植模型,在第30天提取大鼠外周血分离活化T细胞进行体外培养,并进行实验分组,A~D组。A组(对照组),行细胞培养;B组(落新妇甙组),培养液中加入落新妇甙15mg/L;C组,落新妇甙(15mg/L)加p38MAPK抑制剂SB203580(5μmol/L);D组,术后每天落新妇甙(15mg/L)加PI3K/Akt抑制剂LY294002(10μmol/L)。TUNEL法检测T淋巴细胞凋亡情况。RT-PCR和Western blot法检测T细胞p38MAPK和PI3K及Akt下游表达的情况。结果:B组(落新妇甙组)T细胞凋亡指数和p38MAPK表达明显高于对照组,而PI3K/Akt明显低于对照组。C组(落新妇甙加p38MAPK抑制剂组)T细胞凋亡和p38MAPK表达均明显低于B组(落新妇甙组)(P<0.01),PI3K/Akt明显高于对照组,但均与对照组无显著差异(P>0.05)。D组(落新妇甙加PI3K/Akt抑制剂LY294002组)T细胞凋亡和PIK3/Akt表达明显高于对照组,p38MAPK明显低于对照组。结论:落新妇甙诱导大鼠肺移植排斥反应中活化T细胞凋亡与其激活p38MAPK信号传导通路、及抑制PI3K/Akt信号传导通路有关。
SECTION ONE The Establishment of Orthotopic Left Pulmonary Allograft Model in Rats
Objective: To establish rat orthotopic left lung allograft transplantation model by the“cuff-like”vessel and bronchial anastomosis technique. Methods: Sixty male Sprague-Dawley rats were randomly allocated to donors and recipients. Thirty left lung transplantation were performed by using the“cuff-like”vessel and bronchial anastomosis technique. Results: All rats were successfully performed orthotopic left lung allograft transplantation. The mean time for the donor lung (from perfusion to the harvest) was (10±1)mins; the mean time for cuff the vessel and bronchus was (10±4)mins; the mean time for anastomoses was (15±2)mins. The mean operative time was (80±10)mins. The 15d survival rates of rats who received transplants were 86%. Among the rats who received transplants, 2 died of pulmonary edema, 1 died of pulmonary thrombosis, the rest one dies of pneumothorax of the right side. Conclusion: Rat orthotopic left lung transplantation with successive anastomosis in cavity is a valid, reproducible, single and cheap model for studying donor lung preservation, ischemia-reperfusion, acute rejection and chronic rejection about lung transplantation.
SECTION TWO Suppression effect of Astilbin on lung allograft rejection in rats
Objective: Using histopathological rejection grade and observeing the local fibrogenesis to study the suppression effect of Astilbin on lung allograft rejection in rats. Methods: The model of rat left lung transplantation was set up.Sixty lung transplanted rats were divided in to 4 groups randomly: group A were fed with normal saline 1ml per day, group B were fed with CsA 5mg/kg per day, group C were fed with Astilbin 1mg/kg per day, and group D were fed with Astilbin 1mg/kg per day aud CsA 2.5mg/kg per day. Histopathological rejection grade of the lung graft were analyzed in after 30 days (5 rats of each group were chosen). BALF(10 rats of each group were chosen) collected from recipients rats treated with drugs while undergoing rat orthotopic left lung transplantation model was used to stimulate human lung fibroblast cells in vitro. Fibroblast proliferation and typeⅠcollagen synthesis was dectected respectively by MTT and ELISA to evaluate the effect of astilbin. Results: (1) In group B , C and D, the histopathological rejection grade of the lung graft was significantly lower as compared with group A. The histopathological rejection grad of the grafts in group D was significantly lower as compared with group C (P<0.05) and group B (P<0.01). (2) In vitro, the BALF induced fibroblast proliferation and typeⅠcollagen synthesis; (3) Group B, C and D significantly decreased human lung fibroblast cells profliferation for stimulation of the BLAF, especially in Group D (P<0.05) Conclusions: Astilbin significantly decreased human lung fibroblast cells proliferation and typeⅠcollagen synthesis for stimulation of BLAF collected from recipients rats treated with drugs while undergoing lung transplantation, suggesting astilbin may inhibit obliterating bronchiolitis after lung transplantation. Astilbin can suppress lung allograft rejection, and has synergistic reaction with CsA.
SECTION THREE The Mechanism of Astilbin on the Suppression of Lung Allograft Rejection PART ONE
Expression and Implication of CD69, CD25 and CD71 on CD3+ lymphocytes in peripheral blood in the rats with lung transplantation using astilbin
Objectives: To investigate the expression and implication of CD69, CD25 and CD71 on CD3+ lymphocytes in peripheral blood in the rats with lung transplantation using astilbin. Methods: The model of rat left lung transplantation was set up. Ten rats were taking peripheral blood as the control group. Forty lung transplanted rats were divided in to 2 groups randomly: group A were fed with normal saline 1ml per day, group B were fed with Astilbin 1mg/kg per day The lymphocytes from the peripheral blood in rats in different periods and were immunologically labeled by CD3·PE and CD69/CD25/CD71·FIFC. CD3/ CD69, CD3 /CD25 and CD3/CD71 were determined by flow cytometry (FCM). Results: The levels of CD3/ CD69, CD3 /CD25 and CD3/CD71 were markedly higher in the 2 days after the lung transplantation, which means the activated T cells were related to the lung allograft acute rejection. On the 5 days after the lung transplantation, the levels of CD3/ CD69 in group B were significant lower in the group A,(P<0.01), which means the astilbin act on the activated T cells and protect the allograft. Conclusion: Astilbin can act on the activated T cells and suppress lung allograft rejection maybe partially related to its effect in activated T cells.
PART TWO Effect of astilbin on the inducement of apoptosis in activated T cells to suppress acute rejection on rat lung transplantation model.
Objective:To study the suppression effect of Astilbin on lung allograft rejection in rats. Methods: The model of rat left lung transplantation was set up. sixty lung transplanted rats were divided in to 2 groups randomly: control group were fed with normal saline 1ml per day, astilbin group were fed with Astilbin 1mg/kg per day. Survival time of each group, activity of IL-2 in spleen lymph cells , transforming rate of T cells in spleen and apoptosis of T cells were observed. Results: Transforming rate of T cells in spleen was significant lower in the astilbin group than the control group. Activity of IL-2 in spleen lymph cells was 4.25±2.65UI/ml and 23.46±1.82UI/ml respectively in the astilbin group and the control group. There were significant difference between two groups (P<0.05). The astilbin group can effectively derive apoptosis of activated T cells in acute rejection. Conclusions: Astilbin can suppress lung allograft rejection maybe partially related to its lower the IL-2 concentration and IFN-γmRNA of activated T cells , which inducement of apoptosis in activated T cells.
PART THREE Effect of astilbin on activation of p38MAPK and suppression of PI3K/Akt signal pathway in activated T cells of rat lung transplantation model with acute rejection.
Objective: To investigate the effect of astilbin on activation of p38 mitogen activated protein kinase (p38MAPK) and suppression of PI3K/Akt in activated T cells of rat lung transplantation model with acute rejection. Methods: The model of rat left lung transplantation was established. At the day30, activated T cells were taken and cultured. The cultured activated T cells were divided into four groups: Group A: control group, were cultured with PBS; Group B: astilbin group, add astilbin (15mg/L); Group C: add Astilbin(15mg/L) and SB203580(5μmol/L); Group D, Astilbin+LY294002(10μmol/L). Apoptosis of T cells were observed by TUNEL. The expression of p38MAPK and PI3K/Akt were measured by RT-PCR and Western blot. Results: Apoptosis indexes and the expression of p38MAPK in activated T cells in Group B were found significant higher than those of the Group A, while PI3K/Akt was significant lower than Group A.(P<0.01). Apoptosis indexes and the expression of p38MAPK in activated T cells in Group B were found significant higher than those of the Group C, while PI3K/Akt was significant lower than Group C.(P<0.01). Apoptosis indexed and the expression of PI3K/Akt in Group D was significant higher than Group A, while the p38MAPK was significant lower than Group A.(P<0.01).Conclusion: Astilbin induces apoptosis of activated T cells of lung transplantation maybe partially related to its activation expression of p38MAPK and suppression of PI3K/Akt signal pathway. Key words: lung transplantation; astilbin, p38MAPK, PI3K/Akt
引文
1. Asimacopoulos PJ, Molokhia FAS, Pegg CAS, Norman JC. Lung transplantation in the rat. Transplant Proc 1971;3:583-5.
2. Mizuta T, Kawaguchi A, Nakahara K, et al. Simplified rat lung transplantation using a cuff technique. J Thorac Cardiovasc Surg, 1989,97:578-81
3. Sasaki M, Muraoka R, Chiba Y, Hiramatu Y. Influence of pulmonary arterial pressure during flushing on lung preservation. Transplantation 1996;61:22–27.
4. Wang LS, Nakamoto K, Hsieh CM, Miyoshi S, Cooper JD. Influence of temperature of flushing solution on lung preservation. Ann Thorac Surg 1993;55:711–715.
5. DeCampos KN, Keshavjee S, Liu M, Slutsky AS. Optimal inflation volume for hypothermic preservation of rat lungs. J Heart Lung Transplant 1998;17:599–607 Fukuse T, Hirata T, Nakamura T, Kawashima M, Hitomi S, Wada H. Influence of deflated and anaerobic conditions during cold storage on rat lungs. Am J Respir Crit Care Med 1999;160:621–627.
6. Mayank RP, Victor EL, Curtis G, et al. Hyperinflation during lung preservation and increased reperfusion injury. Journal of Surgical Research, 2005,123:134-138
7. Kao SJ, Wang D, Yeh DY, et al. Static inflation attenuates ischemia/reperfusion injury in an isolated rat lung in situ. Chest, 2004, 126(2):552-558
1. Trulock EP, Edward LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung transplantation: twenty-second official adult lung and heart-lung transplant report ---2005, 24: 956-967
2. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4–13.
3. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999;159:829–833.
4. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114:195–202
5. Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Aloush A, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005;5:2022–2030.
6. Yan R, Xu Q. Astilbin selectively facilitates the apoptosis of interlenkin-2-dependent phytohemagglutinin-activated jurkat cells. Pharmacol Res 2001,44(2):135-139
7. Han LK,et al. Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes. J Nat Prod 1998;61(8):1006-11
8. Yousem SA, et al. A revision of the 1990 Working Formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplantation. 1996;15:1~15
9.史菲,邱晨。大鼠支气管肺泡灌洗术标准化操作的探讨。中国现代医学杂志,2002,12(24):67-69
10.徐进志,姜哲,腾哈乐,等。缬沙坦抑制大鼠移植气管中的上清液诱导肺成纤维细胞活性的体外实验。中华气管移植杂志,2007,28(2):89-91]
11. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1235 transbrochial lung biopsies in lung transplant recipients. J Heart Lung Transplant, 2002, 21(10): 1 062-1 067
12.杨国仪,陈静瑜,史金兰,等.肺移植急性排斥反应3例报道及文献复习.中国现代医学杂志,2006,16(6):950-952
13.陈静瑜,郑明峰,何毅军,等.单肺移植治疗终末期肺气肿。中华外科杂志,2003,41:404- 406
14. Sharples LD, MacNeil K, Stewart S, et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002; 21(2): 271-281
15. Yousem S, Berry G, Cagle P, Chamberlain D, Husain A, Hruban R, Marchevsky A, Ohori N, Ritter J, Stewart S, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplantation. 1996;15:1~15
16. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4–13.
17. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999;159:829–833. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114:195–202
18.易定华。心脏移植和心肺移植现状与相关问题的探讨。第四军医大学学报,2005,26(23):2113-2115
19. Mcadam A J, Gewurz B, Farkash EA, et al. Either B7 costimulation or IL-2 can elicit genaration of primary alloreactive CTL. J Immunol, 2000, 165: 3 088～3 093
20.高立平,王建军,高博等。FK506对心脏移植急性排斥反应Fax和Fas-L mRNA表达的影响[J]。河北医科大学学报,2005,26(6):423-426
21.卢静,张瑞雯,力弘。环孢素不良反应发生机制和对策[J]。中国临床药学杂志,2005,14(4):260-262
22.吴丽明,张敏。土茯苓中落新妇甙的利尿镇痛作用。中药材,1995,18(12):627-630
23. Qiang Xu, Feihua Wu, Jingsong Cao, et al. Astilbin selectively dysfunction of liver-infiltrating cells----novels protection from liver damage. European Journal of Phamacology, 1999,377:93-100
24. Y.Cai,T.Chen and Q.Xu. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm. Res. 2003, 52:334-340
25.高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3:1693-1694
26.高思海,陈涛,潘铁成。落新妇甙对同种反应性T细胞Bax,Bcl-2和caspase-3表达的影响。中华实用中西医杂志,2003, 3:2110-2111
27.高思海,李平,潘铁成。落新妇甙对同种反应性T细胞Fas,FasL和TNF-R1和TNF-R2基因表达的调控。中华实用中西医杂志,2004,4:217-218
28.高思海,李平,陈涛,等。落新妇甙对小鼠心脏移植后移植物血管病的抑制作用。中华器官移植杂志,2005,26(11):682-683
29. Han LK, Ninomiya H, Taniguchi M, et al. Norepinephrine-augmenting lipolytic effectors from astilbe thunbergii rhizomes. J Nat Prod, 1998,61:1006-1011
30. Motoyashiki T, Miyake M, Morita T, et al. Enhancement of the vanadate-stimulated relaease of lipoprotein lapase activity by astilbin from the leaves of engelhardtia chrysolepis. Biol Pharm Bull, 1998, 21: 517-519
31.胡军一,导师:段宏泉。药用植物青刺尖和落新妇生物活性成分的研究,第四章,落新妇化学成分及药理学研究进展。2006年,天津大学,博士论文,应用化学类,34-36
32. Dosanjh A, Ikonen T, Wan B, et al. Effects of valsartan on bleomycin-induced pulmonary fibrosis in rats and the expression of hepatocyte growth factor in lung tissue. Chin J Tuberc Respir Dis, 2005,28(7):497-483
33. Slebos DJ, Postma DS, Koeter GH, van der Bij W, Boezen M, Kauffman HF.Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. J Heart Lung Transplant. 2004;23:532-540
34. Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W, Burckart G, Smaldone G, Pham S, Ohori NP, et al. Interleukin 6 and interferongamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation 1997;64:263–269.
35. Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan SC, Ross D. Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clin Transplant 1999;13:201–207.
36. Ross DJ, Moudgil A, Bagga A, Toyoda M, Marchevsky AM, Kass RM, Jordan SC. Lung allograft dysfunction correlates with gamma-interferon gene expression in bronchoalveolar lavage. J Heart Lung Transplant 1999;18:627–636.
37. Magnan A, Mege JL, Reynaud M, Thomas P, Capo C, Garbe L, Meric B, Badier M, Bongrand P, Viard L. Monitoring of alveolar macrophage production of tumor necrosis factor-αand interleukin-6 in lung transplantrecipients. Marseille and Montreal Lung Transplantation Group.Am J Respir Crit Care Med 1994;150:684–689.
38. Magnan A, Mege JL, Escallier JC, Brisse J, Capo C, Reynaud M, Thomas P, Meric B, Garbe L, Badier M, et al. Balance between alveolar macrophage IL-6 and TGF-βin lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med 1996;153:1431–1436
39. Whitehead BF, Stoehr C, Wu CJ, Patterson G, Burchard EG, Theodore J, Clayberger C, Starnes VA. Cytokine gene expression in human lung transplant recipients. Transplantation 1993;56:956–961.
40. Clement MV, Legros-Maida S, Israel-Biet D, Carnot F, Soulie A, Reynaud P, Guillet J, Gandjbakch I, Sasportes M. Perforin and granzyme B expression is associated with severe acute rejection: evidence for in situ localization in alveolar lymphocytes of lung-transplanted patients. Transplantation 1994;57:322–326.
41. Shi R, Yang J, JaramilloA, Steward NS,AloushA, Trulock EP,Alexander PG, Suthanthiran M, Mohanakumar T. Correlation between interleukin-15 and granzyme B expression and acute lung allograft rejection. Transpl Immunol 2004;12:103–108.
1.徐强,等。选择性抑制活化T淋巴细胞的功能----从中药及其成分中发现的崭新作用模式。哈尔滨商业大学学报,2001,17(2):7~9
2. Xu Q, Wu F, Cao J, et al. Astilbin selectively induces dysfunction of liver-infiltrating cells ---novel protection from liver damage. Eur J Pharmacol, 1999, 377: 93-100 Rekelmam P, Van-Soest P, Leenen PJ, et al. Inhibition of proliferation and differentiation during early T cell development by anti-transferin receptor antibody. Eur J Immunol, 1994,24:2896-2902
3.钟红兴,苏泽轩,邓文封,等。肾移植术后外周血CD3+细胞CD69、CD25及CD71的表达及意义。中华器官移植杂志。2000,21(4):201-201
4.梁兆端,黄秀艳,肇静娴,等。芹菜素对小鼠T淋巴细胞体外活化和增殖的抑制作用。现代免疫学,2007,27(6):481-487
5. Ashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation, 1999,67:110-115
6. Richter NG, Raddatz G, Steinhoff H, et al. Transmission of donor lymphocytes in clinical lung transplantation. Transplant. Int. 7:414
7. Navarro F, P Portales, JP Pageaux, et al. Natural killer cell andαβandγδlymphocyte traffic into the liver graft immediately after liver transplantation. Transplnatation, 2000,69:633
8. Marc DP, Kevin Y, Yumiko Imai,et al. Recipient T cells mediate reperfusion injury after lung transplantation in the rat. The Journal of Immunology, 2003,171:4995-5002
9. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation[J]. Science, 1999, 163(1):130-136
1. Nicod LP, Joudrier S, Isler P, Spiliopoulos A, Pache JC. Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation. J Heart Lung Transplant. 2005 Aug;24(8):1067-75
2. Trivedi HL. Immunobiology of rejection and adaptation. Transplant Proc. 2007 Apr;39(3):647-52
3. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 2000,47:85
4.朱晓黎,黄河,等。免疫抑制剂对人外周血活化T淋巴细胞凋亡的影响。浙江医学,2005,27(10):721-724 Izeradjene K. Apoptosis of superantigen-activated T cells induced mycophenolate mofeti treatment. Transplantation, 2001,71(1):118
5. Vathsala A, et al. Inhibition of apoptosis in anti-CD3-treated peripheral blood lymphocytes by immunosuppressive drugs. Transplantation Proceedings, 2000,32:1992
6. Valentine VG, Robbins RC, Wehner JH, et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest, 1996,109:1184-1189
7. Woodward JE, Schaefer AT, Zottola LB, et al. Inhibition of in vitro donor-specific proliferative and cytotoxic T cell responses in chimeric CD40 ligand-deficient bone marrow transplant recipients treated peri-operatively with CTLA4-Ig. Transplant Proc, 2001,33:113-114
8. Kiani A, Garcia-Cozar FJ, Habermann I, et al. Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood, 2001,98:1480-1488
9. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev, 2003, 193:70-81]
10.高思海,李平,潘铁成,等。落新妇甙诱导小鼠心脏移植体外排斥反应中活化T细胞凋亡。中华实验外科杂志,2004,21(4):502
11.肖序仁,徐衍盛,敖建华。不同免疫抑制剂诱导外周血活化T淋巴细胞凋亡的研究。中华器官移植杂志2006,27(11):644-647
12. Yan R, Xu Q. Astilbin selectively facilitates the apoptosis of interlenkin-2-dependent phytohemagglutinin-activated jurkat cells. Pharmacol Res 2001; 44(2):135-9
13.崔丽丽,于波。苏木水提取物的抗急性排斥与Th1/Th2免疫偏移作用。中国胸心血管外科临床杂志。2006,13(4):255-259
14. Sun J, Wang X, Wang C, et al. Increased Fas ligand expression and activated T-lymphocyte apoptosis in islet graft tolerance induced by liver transplantation. Transplantation proceedings, 2001 Feb-Mar, 33(1-2):227-8
15. Larsen CP, Knechtle SJ, Adams A, et al. A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. American Journal of Transplantation. May 2006Vol. 6, no. 5, 876-883.
16. Monk NJ, Hargreaves REG, Simpson E, et al. Transplant tolerance: models, concepts and facts. Journal of molecular medicine (Berlin, Germany), 2006 Apr, 84(4):295-304.
17. Hartwiq MG, Appel JZ, Li B, et al. Chronic aspiration of gastric fluid accelerates pulmonary allograft dysfunction in a rat model of lung transplantation. The Journal of thoracic and cardiovascular surgery, 2006 Jan, 131(1):209-17.
1. Tanaka N, Kamanaka M, Enslen H, et al. Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. [J]. EMBO Rep, 2002,3(8):785-791
2.刘力,傅新元。T淋巴细胞的信号转导。第二军医大学学报,2002,23(10):1063-1065
3. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev, 2003, 193:70-81
4. Mcadam AJ, Gewurz B, Farkash EA, et al.Either B7costimulation or IL-2 can elicit generation of primary alloreactive CTL. J Immunol, 2000, 165:3088-3093
5. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem, 1998, 67: 481-507
6. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 2004;9:667-676
7. Varadhachary A S,Peter M E,Perdow S N,et al. Selective Up-Regulation of Phosphatidylinositol 3'-Kinase Activity in Th2 Cells Inhibits Caspase-8 Cleavage at the Death-Inducing Complex: A Mechanism for Th2 Resistance from Fas-Mediated Apoptosis. J Immunol 1999;163(9): 4772-4779.
8. Aronica M A, Goenka S, Boothby M. IL-4-dependent induction of BCL-2 and BCL-X(L)in activated T lymphocytes through a STAT6- and pi3-kinase-independent pathway. Cytokine. 2000;12(6):578-87.
9. Downward J . Lipid regulated kinases : some common themes at last . Science , 1998 , 279∶673～675
10. Vlahos CJ,Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one-(LY294002). J Biol Chem, 1994, 269: 5241-5248
11. WOO SC, CHIN KS. Inhibition of phosphatidylinositol-3 kinase enhances insulin stimulation of insulin receptor substrate 1 tyrosine phosphorylation and extracellular signal-regulated kinases in mouse R fibroblasts. [J]. J Recept Signal Transduct Res,2005,24(1-2):67-83
12.宋华培,颜洪,党永明等。磷脂酰肌醇3激酶抑制剂LY294002对缺血缺氧心肌细胞的作用研究。现代生物医学进展,2007,7(11):1659-1661
13. Maulon L ,Guerin S ,Ricci J E , et al . T-Cell receptor signaling pathway exerts a negative control on thrombin-mediated increase in [Ca2+] i and p38 MAPK activation in Jurkat T cells:implication of the tyrosine kinase p56Lck [J ] . Blood ,199 8,91(11):4232-4241.
14. Herrant M ,Luciano F ,Loubat A ,et al . The protective effect of phorbol esters on Fas2mediated apoptosis in T cell s. Transcriptional and post ranscriptional regulation [ J ] . Oncogene , 2002,21 (32) :4957-4968
15.高思海,李平,陈涛,等。落新妇甙对心脏移植排斥反应中活化T细胞p38丝裂原激活蛋白激酶信号传导通路的影响。中国医院药学杂志,2007,27(2):153-156
16.高思海,李平,潘铁成,等。落新妇甙对同种反应性T细胞Fas,FasL和TNF-R1和TNF-R2基因表达的调控。中华使用中医医杂志,2004,4:217-218
2. Mizuta T, Kawaguchi A, Nakahara K, et al. Simplified rat lung transplantation using a cuff technique. J Thorac Cardiovasc Surg, 1989,97:578-81
3. Sasaki M, Muraoka R, Chiba Y, Hiramatu Y. Influence of pulmonary arterial pressure during flushing on lung preservation. Transplantation 1996;61:22–27.
4. Wang LS, Nakamoto K, Hsieh CM, Miyoshi S, Cooper JD. Influence of temperature of flushing solution on lung preservation. Ann Thorac Surg 1993;55:711–715.
5. DeCampos KN, Keshavjee S, Liu M, Slutsky AS. Optimal inflation volume for hypothermic preservation of rat lungs. J Heart Lung Transplant 1998;17:599–607 Fukuse T, Hirata T, Nakamura T, Kawashima M, Hitomi S, Wada H. Influence of deflated and anaerobic conditions during cold storage on rat lungs. Am J Respir Crit Care Med 1999;160:621–627.
6. Mayank RP, Victor EL, Curtis G, et al. Hyperinflation during lung preservation and increased reperfusion injury. Journal of Surgical Research, 2005,123:134-138
7. Kao SJ, Wang D, Yeh DY, et al. Static inflation attenuates ischemia/reperfusion injury in an isolated rat lung in situ. Chest, 2004, 126(2):552-558
1. Trulock EP, Edward LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung transplantation: twenty-second official adult lung and heart-lung transplant report ---2005, 24: 956-967
2. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4–13.
3. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999;159:829–833.
4. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114:195–202
5. Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Aloush A, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005;5:2022–2030.
6. Yan R, Xu Q. Astilbin selectively facilitates the apoptosis of interlenkin-2-dependent phytohemagglutinin-activated jurkat cells. Pharmacol Res 2001,44(2):135-139
7. Han LK,et al. Norepinephrine-augmenting lipolytic effectors from Astilbe thunbergii rhizomes. J Nat Prod 1998;61(8):1006-11
8. Yousem SA, et al. A revision of the 1990 Working Formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplantation. 1996;15:1~15
9.史菲,邱晨。大鼠支气管肺泡灌洗术标准化操作的探讨。中国现代医学杂志,2002,12(24):67-69
10.徐进志,姜哲,腾哈乐,等。缬沙坦抑制大鼠移植气管中的上清液诱导肺成纤维细胞活性的体外实验。中华气管移植杂志,2007,28(2):89-91]
11. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1235 transbrochial lung biopsies in lung transplant recipients. J Heart Lung Transplant, 2002, 21(10): 1 062-1 067
12.杨国仪,陈静瑜,史金兰,等.肺移植急性排斥反应3例报道及文献复习.中国现代医学杂志,2006,16(6):950-952
13.陈静瑜,郑明峰,何毅军,等.单肺移植治疗终末期肺气肿。中华外科杂志,2003,41:404- 406
14. Sharples LD, MacNeil K, Stewart S, et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002; 21(2): 271-281
15. Yousem S, Berry G, Cagle P, Chamberlain D, Husain A, Hruban R, Marchevsky A, Ohori N, Ritter J, Stewart S, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplantation. 1996;15:1~15
16. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4–13.
17. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999;159:829–833. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM III. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114:195–202
18.易定华。心脏移植和心肺移植现状与相关问题的探讨。第四军医大学学报,2005,26(23):2113-2115
19. Mcadam A J, Gewurz B, Farkash EA, et al. Either B7 costimulation or IL-2 can elicit genaration of primary alloreactive CTL. J Immunol, 2000, 165: 3 088～3 093
20.高立平,王建军,高博等。FK506对心脏移植急性排斥反应Fax和Fas-L mRNA表达的影响[J]。河北医科大学学报,2005,26(6):423-426
21.卢静,张瑞雯,力弘。环孢素不良反应发生机制和对策[J]。中国临床药学杂志,2005,14(4):260-262
22.吴丽明,张敏。土茯苓中落新妇甙的利尿镇痛作用。中药材,1995,18(12):627-630
23. Qiang Xu, Feihua Wu, Jingsong Cao, et al. Astilbin selectively dysfunction of liver-infiltrating cells----novels protection from liver damage. European Journal of Phamacology, 1999,377:93-100
24. Y.Cai,T.Chen and Q.Xu. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm. Res. 2003, 52:334-340
25.高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3:1693-1694
26.高思海,陈涛,潘铁成。落新妇甙对同种反应性T细胞Bax,Bcl-2和caspase-3表达的影响。中华实用中西医杂志,2003, 3:2110-2111
27.高思海,李平,潘铁成。落新妇甙对同种反应性T细胞Fas,FasL和TNF-R1和TNF-R2基因表达的调控。中华实用中西医杂志,2004,4:217-218
28.高思海,李平,陈涛,等。落新妇甙对小鼠心脏移植后移植物血管病的抑制作用。中华器官移植杂志,2005,26(11):682-683
29. Han LK, Ninomiya H, Taniguchi M, et al. Norepinephrine-augmenting lipolytic effectors from astilbe thunbergii rhizomes. J Nat Prod, 1998,61:1006-1011
30. Motoyashiki T, Miyake M, Morita T, et al. Enhancement of the vanadate-stimulated relaease of lipoprotein lapase activity by astilbin from the leaves of engelhardtia chrysolepis. Biol Pharm Bull, 1998, 21: 517-519
31.胡军一,导师:段宏泉。药用植物青刺尖和落新妇生物活性成分的研究,第四章,落新妇化学成分及药理学研究进展。2006年,天津大学,博士论文,应用化学类,34-36
32. Dosanjh A, Ikonen T, Wan B, et al. Effects of valsartan on bleomycin-induced pulmonary fibrosis in rats and the expression of hepatocyte growth factor in lung tissue. Chin J Tuberc Respir Dis, 2005,28(7):497-483
33. Slebos DJ, Postma DS, Koeter GH, van der Bij W, Boezen M, Kauffman HF.Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. J Heart Lung Transplant. 2004;23:532-540
34. Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W, Burckart G, Smaldone G, Pham S, Ohori NP, et al. Interleukin 6 and interferongamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation 1997;64:263–269.
35. Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan SC, Ross D. Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clin Transplant 1999;13:201–207.
36. Ross DJ, Moudgil A, Bagga A, Toyoda M, Marchevsky AM, Kass RM, Jordan SC. Lung allograft dysfunction correlates with gamma-interferon gene expression in bronchoalveolar lavage. J Heart Lung Transplant 1999;18:627–636.
37. Magnan A, Mege JL, Reynaud M, Thomas P, Capo C, Garbe L, Meric B, Badier M, Bongrand P, Viard L. Monitoring of alveolar macrophage production of tumor necrosis factor-αand interleukin-6 in lung transplantrecipients. Marseille and Montreal Lung Transplantation Group.Am J Respir Crit Care Med 1994;150:684–689.
38. Magnan A, Mege JL, Escallier JC, Brisse J, Capo C, Reynaud M, Thomas P, Meric B, Garbe L, Badier M, et al. Balance between alveolar macrophage IL-6 and TGF-βin lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med 1996;153:1431–1436
39. Whitehead BF, Stoehr C, Wu CJ, Patterson G, Burchard EG, Theodore J, Clayberger C, Starnes VA. Cytokine gene expression in human lung transplant recipients. Transplantation 1993;56:956–961.
40. Clement MV, Legros-Maida S, Israel-Biet D, Carnot F, Soulie A, Reynaud P, Guillet J, Gandjbakch I, Sasportes M. Perforin and granzyme B expression is associated with severe acute rejection: evidence for in situ localization in alveolar lymphocytes of lung-transplanted patients. Transplantation 1994;57:322–326.
41. Shi R, Yang J, JaramilloA, Steward NS,AloushA, Trulock EP,Alexander PG, Suthanthiran M, Mohanakumar T. Correlation between interleukin-15 and granzyme B expression and acute lung allograft rejection. Transpl Immunol 2004;12:103–108.
1.徐强,等。选择性抑制活化T淋巴细胞的功能----从中药及其成分中发现的崭新作用模式。哈尔滨商业大学学报,2001,17(2):7~9
2. Xu Q, Wu F, Cao J, et al. Astilbin selectively induces dysfunction of liver-infiltrating cells ---novel protection from liver damage. Eur J Pharmacol, 1999, 377: 93-100 Rekelmam P, Van-Soest P, Leenen PJ, et al. Inhibition of proliferation and differentiation during early T cell development by anti-transferin receptor antibody. Eur J Immunol, 1994,24:2896-2902
3.钟红兴,苏泽轩,邓文封,等。肾移植术后外周血CD3+细胞CD69、CD25及CD71的表达及意义。中华器官移植杂志。2000,21(4):201-201
4.梁兆端,黄秀艳,肇静娴,等。芹菜素对小鼠T淋巴细胞体外活化和增殖的抑制作用。现代免疫学,2007,27(6):481-487
5. Ashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation, 1999,67:110-115
6. Richter NG, Raddatz G, Steinhoff H, et al. Transmission of donor lymphocytes in clinical lung transplantation. Transplant. Int. 7:414
7. Navarro F, P Portales, JP Pageaux, et al. Natural killer cell andαβandγδlymphocyte traffic into the liver graft immediately after liver transplantation. Transplnatation, 2000,69:633
8. Marc DP, Kevin Y, Yumiko Imai,et al. Recipient T cells mediate reperfusion injury after lung transplantation in the rat. The Journal of Immunology, 2003,171:4995-5002
9. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation[J]. Science, 1999, 163(1):130-136
1. Nicod LP, Joudrier S, Isler P, Spiliopoulos A, Pache JC. Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation. J Heart Lung Transplant. 2005 Aug;24(8):1067-75
2. Trivedi HL. Immunobiology of rejection and adaptation. Transplant Proc. 2007 Apr;39(3):647-52
3. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 2000,47:85
4.朱晓黎,黄河,等。免疫抑制剂对人外周血活化T淋巴细胞凋亡的影响。浙江医学,2005,27(10):721-724 Izeradjene K. Apoptosis of superantigen-activated T cells induced mycophenolate mofeti treatment. Transplantation, 2001,71(1):118
5. Vathsala A, et al. Inhibition of apoptosis in anti-CD3-treated peripheral blood lymphocytes by immunosuppressive drugs. Transplantation Proceedings, 2000,32:1992
6. Valentine VG, Robbins RC, Wehner JH, et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest, 1996,109:1184-1189
7. Woodward JE, Schaefer AT, Zottola LB, et al. Inhibition of in vitro donor-specific proliferative and cytotoxic T cell responses in chimeric CD40 ligand-deficient bone marrow transplant recipients treated peri-operatively with CTLA4-Ig. Transplant Proc, 2001,33:113-114
8. Kiani A, Garcia-Cozar FJ, Habermann I, et al. Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood, 2001,98:1480-1488
9. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev, 2003, 193:70-81]
10.高思海,李平,潘铁成,等。落新妇甙诱导小鼠心脏移植体外排斥反应中活化T细胞凋亡。中华实验外科杂志,2004,21(4):502
11.肖序仁,徐衍盛,敖建华。不同免疫抑制剂诱导外周血活化T淋巴细胞凋亡的研究。中华器官移植杂志2006,27(11):644-647
12. Yan R, Xu Q. Astilbin selectively facilitates the apoptosis of interlenkin-2-dependent phytohemagglutinin-activated jurkat cells. Pharmacol Res 2001; 44(2):135-9
13.崔丽丽,于波。苏木水提取物的抗急性排斥与Th1/Th2免疫偏移作用。中国胸心血管外科临床杂志。2006,13(4):255-259
14. Sun J, Wang X, Wang C, et al. Increased Fas ligand expression and activated T-lymphocyte apoptosis in islet graft tolerance induced by liver transplantation. Transplantation proceedings, 2001 Feb-Mar, 33(1-2):227-8
15. Larsen CP, Knechtle SJ, Adams A, et al. A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. American Journal of Transplantation. May 2006Vol. 6, no. 5, 876-883.
16. Monk NJ, Hargreaves REG, Simpson E, et al. Transplant tolerance: models, concepts and facts. Journal of molecular medicine (Berlin, Germany), 2006 Apr, 84(4):295-304.
17. Hartwiq MG, Appel JZ, Li B, et al. Chronic aspiration of gastric fluid accelerates pulmonary allograft dysfunction in a rat model of lung transplantation. The Journal of thoracic and cardiovascular surgery, 2006 Jan, 131(1):209-17.
1. Tanaka N, Kamanaka M, Enslen H, et al. Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. [J]. EMBO Rep, 2002,3(8):785-791
2.刘力,傅新元。T淋巴细胞的信号转导。第二军医大学学报,2002,23(10):1063-1065
3. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev, 2003, 193:70-81
4. Mcadam AJ, Gewurz B, Farkash EA, et al.Either B7costimulation or IL-2 can elicit generation of primary alloreactive CTL. J Immunol, 2000, 165:3088-3093
5. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem, 1998, 67: 481-507
6. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 2004;9:667-676
7. Varadhachary A S,Peter M E,Perdow S N,et al. Selective Up-Regulation of Phosphatidylinositol 3'-Kinase Activity in Th2 Cells Inhibits Caspase-8 Cleavage at the Death-Inducing Complex: A Mechanism for Th2 Resistance from Fas-Mediated Apoptosis. J Immunol 1999;163(9): 4772-4779.
8. Aronica M A, Goenka S, Boothby M. IL-4-dependent induction of BCL-2 and BCL-X(L)in activated T lymphocytes through a STAT6- and pi3-kinase-independent pathway. Cytokine. 2000;12(6):578-87.
9. Downward J . Lipid regulated kinases : some common themes at last . Science , 1998 , 279∶673～675
10. Vlahos CJ,Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one-(LY294002). J Biol Chem, 1994, 269: 5241-5248
11. WOO SC, CHIN KS. Inhibition of phosphatidylinositol-3 kinase enhances insulin stimulation of insulin receptor substrate 1 tyrosine phosphorylation and extracellular signal-regulated kinases in mouse R fibroblasts. [J]. J Recept Signal Transduct Res,2005,24(1-2):67-83
12.宋华培,颜洪,党永明等。磷脂酰肌醇3激酶抑制剂LY294002对缺血缺氧心肌细胞的作用研究。现代生物医学进展,2007,7(11):1659-1661
13. Maulon L ,Guerin S ,Ricci J E , et al . T-Cell receptor signaling pathway exerts a negative control on thrombin-mediated increase in [Ca2+] i and p38 MAPK activation in Jurkat T cells:implication of the tyrosine kinase p56Lck [J ] . Blood ,199 8,91(11):4232-4241.
14. Herrant M ,Luciano F ,Loubat A ,et al . The protective effect of phorbol esters on Fas2mediated apoptosis in T cell s. Transcriptional and post ranscriptional regulation [ J ] . Oncogene , 2002,21 (32) :4957-4968
15.高思海,李平,陈涛,等。落新妇甙对心脏移植排斥反应中活化T细胞p38丝裂原激活蛋白激酶信号传导通路的影响。中国医院药学杂志,2007,27(2):153-156
16.高思海,李平,潘铁成,等。落新妇甙对同种反应性T细胞Fas,FasL和TNF-R1和TNF-R2基因表达的调控。中华使用中医医杂志,2004,4:217-218
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |